A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis

Trial Profile

A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs NGM 282 (Primary)
  • Indications Primary sclerosing cholangitis
  • Focus Therapeutic Use
  • Sponsors NGM Biopharmaceuticals
  • Most Recent Events

    • 13 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 31 Aug 2017 This trial has been completed in Netherlands , according to European Clinical Trials Database.
    • 07 Mar 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top